EQS-News: Formycon AG / Key word(s): Market ReportFormycon Ranibizumab Biosimilar FYB201/CIMERLI® achieved a market share of 38% in the United States in December 202318.01.2024 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement. Press Release // January 18, 2024 Formycon Ranibizumab Biosimilar FYB201/CIMERLI® achieved a market share of 38% in the United States in December 2023Munich, Germany – Formycon AG (FWB: FYB) today announced that its commercialization partner, Coherus BioSciences, Inc. has released new sales figures for CIMERLI®1 (Ranibizumab-eqrn) in the US. In December 2023, CIMERLI® achieved a market share of 38% by volume in the US Ranibizumab market4 and thereby continues to be the most successful biosimilar in this segment. Formycon AG assumes no obligation to update these forward-looking statements or to correct them in case of developments which differ from those anticipated. No public offering of securities of Formycon AG will be made nor is a public offering intended.
